Colon delivery of budesonide using solid dispersion in Dextran for the treatment and secondary prevention of ulcerative colitis in Rat

International Journal of Preventive Medicine

Volumn 1, Issue 2, 2010, Pages 115-123

  Varshosaz, Jaleh ^a   Ahmadi, Fatemeh ^a   Emami, Jaber ^a   Tavakoli, Naser ^a   Minaiyan, Mohsen ^a   Mahzouni, Parvin ^a   Dorkoosh, Farid ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Budesonide; Colon delivery; Dextran; Solid dispersion; Ulcerative colitis

Indexed keywords

BUDESONIDE; DEXTRAN; MESALAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON MUCOSA; CONTROLLED STUDY; DISPERSION; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG RELEASE; DRUG SOLUBILITY; IN VIVO STUDY; MALE; MOLECULAR WEIGHT; NONHUMAN; RAT; SECONDARY PREVENTION; SUSPENSION; TABLET FORMULATION; ULCERATIVE COLITIS;

EID: 79952048160     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Knigge KL. Inflammatory bowel disease. Clin Cornerstone 2002; 4(4): 49-60.
2. Friend DR. Review article: issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 1998; 12(7): 591-603.
3. Bickston SJ, Cominelli F. Inflammatory bowel disease: short- and long- term treatments. Dis Mon 1998; 144: 141-72
4. Klotz U, Schwab M. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Adv Drug Deliv Rev 2005; 57(2): 267-79.
5. Edsbacker S, Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clin Pharmacokinet 2004; 43(12): 803-21.
6. Fedorak RN, Bistritz L. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv Drug Deliv Rev 2005; 57(2): 303-16.
7. McKeage K, Goa KL. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn's disease in adults. Drugs 2002; 62(15): 2263-82.
8. Krishnamachari Y, Madan P, Lin S. Development of pH- and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon. Int J Pharm 2007; 338(1-2): 238-47.
9. Rodriguez M, Vila-Jato JL, Torres D. Design of a new multiparticulate system for potential sitespecific and controlled drug delivery to the colonic region. J Control Release 1998; 55(1): 67-77.
10. Yehia SA, Elshafeey AH, Sayed I, Shehata AH. Optimization of budesonide compression-coated tablets for colonic delivery. AAPS PharmSciTech 2009; 10(1): 147-57.
11. Varshosaz J, Emami J, Tavakoli N, Fassihi A, Minaiyan M, Ahmadi F, et al. Synthesis and evaluation of dextran-budesonide conjugates as colon specific prodrugs for treatment of ulcerative colitis. Int J Pharm 2009; 365(1-2): 69-76.
12. Takeuchi H, Nagira S, Tanimura S, Yamamoto H, Kawashima Y. Tabletting of solid dispersion particles consisting of indomethacin and porous silica particles. Chem Pharm Bull (Tokyo) 2005; 53(5): 487-91.
13. The United States pharmacopeia & national formulary. Rockville: United States Pharmacopeial Convention, Inc; 2007.
14. Aslan A, Temiz M, Atik E, Polat G, Sahinler N, Besirov E, et al. Effectiveness of mesalamine and propolis in experimental colitis. Adv Ther 2007; 24(5): 1085-97.
15. Gorgulu S, Yagci G, Kaymakcioglu N, Ozkara M, Kurt B, Ozcan A, et al. Hyperbaric oxygen enhances the efficiency of 5-aminosalicylic acid in acetic acidinduced colitis in rats. Dig Dis Sci 2006; 51(3): 480-7.
16. El Medany A, Mahgoub A, Mustafa A, Arafa M, Morsi M. The effects of selective cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, on experimental colitis induced by acetic acid in rats. Eur J Pharmacol 2005; 507(1-3): 291-9.
17. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993; 69(2): 238-49.
18. Williams KL, Fuller CR, Dieleman LA, DaCosta CM, Haldeman KM, Sartor RB, et al. Enhanced survival and mucosal repair after dextran sodium sulfate- induced colitis in transgenic mice that overexpress growth hormone. Gastroenterology 2001; 120(4): 925-37.
19. Dieleman LA, Palmen MJ, Akol H, Bloemena E, Pena AS, Meuwissen SG, et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 1998; 114(3): 385-91.
20. Gennaro AR. Remington: The science and practice of pharmacy. Philadelphia: Lippincott Williams & Wilkins; 2000.
21. Desai J, Alexander K, Riga A. Characterization of polymeric dispersions of dimenhydrinate in ethyl cellulose for controlled release. Int J Pharm 2006; 308(1-2): 115-23.
22. Dastmalchi S, Garjani A, Maleki N, Sheikhee G, Baghchevan V, Jafari-Azad P, et al. Enhancing dissolution, serum concentrations and hypoglycemic effect of glibenclamide using solvent deposition technique. J Pharm Pharm Sci 2005; 8(2): 175-81.
23. Gil EC, Colarte AI, Bataille B, Pedraz JL, Rodriguez F, Heinamaki J. Development and optimization of a novel sustained-release dextran tablet formulation for propranolol hydrochloride. Int J Pharm 2006; 317(1): 32-9.
24. Paiva LA, Gurgel LA, De Sousa ET, Silveira ER, Silva RM, Santos FA, et al. Protective effect of Copaifera langsdorffii oleo-resin against acetic acidinduced colitis in rats. J Ethnopharmacol 2004; 93(1): 51-6.